• 700 Main St. E., Hamilton, Ontario
  • Hundreds of participants expected
  • Friendly and informed team
Start live chat

Are you using Paxlovid in Hamilton? 

Join a Research Study with Dr. Rick Tytus!

Some individuals with COVID-19 might experience a return of symptoms even after initial improvement, including those who’ve received treatment like Paxlovid. Connect with our team to explore this research opportunity.
  • Contribute to the advancement of potential new treatments 😷
  • Receive study-related medical care throughout the study​
  • Proudly based in 🇨🇦 Hamilton since 1988
See if you're eligible
Discover more

Research Ethics Board approved. No pressure, just information.

Meet Richard Tytus, Family Doctor & Founder of Hamilton Medical Research Group

My vision: A community in which everyone is able to achieve their optimal level of health and wellness by enabling the introduction and innovation of new treatments and therapies.
Dr. Richard Tytus practised as a GP anesthetist for five years in Blind River, Ontario, before practising in downtown Hamilton. He is an associate clinical professor in the Department of Family Medicine at McMaster University. Dr. Tytus served as president of the Hamilton Academy of Medicine and is currently a director of the Ontario Medical Association (OMA) Board (District 4).
 
Dr. Tytus has received numerous awards, including the 2012 Family Physician of the Year presented by the Ontario College of Family Physicians.
Are you eligible to participate?

Play an active role in your health care today!

See if you're eligible
Discover more
Dr. Richard Tytus is the Founder and Principal Investigator at the Hamilton Medical Research Group (HMRG)
Hamilton Medical Research Group
700 Main Street East
Hamilton, Ontario  L8M 1K7
 

© Copyright 2023, All Rights Reserved by Banty (our partner in clinical trial recruitment)

Study Summary

If you are taking PAXLOVID and are interested in seeing if you qualify for a clinical trial, it is important that you monitor your COVID-19 symptoms for 14 days following your last dose to help determine whether you experience COVID-19 symptom rebound.

The Pfizer C4671042 clinical trial is evaluating if an additional 5-day course of PAXLOVID may provide benefit for adults with rebound of COVID-19 symptoms and a SARS-CoV-2 infection within 14 days after completing an initial 5-day course of PAXLOVID.

Being in the study is voluntary. Even if you decide to join and then change your mind, you can stop participating at any time.

People who are eligible for this clinical trial can expect to be enrolled in the study for about 24 weeks and will need to attend at least 10 study visits in-person or over the phone/video.

Participants will be randomly assigned to receive the study drug or placebo. The study doctor will not know who has been assigned to which drug.

PAXLOVID (nirmatrelvir and ritonavir) or placebo (drug with no active ingredient) and ritonavir, will need to be taken by mouth twice daily for 5 days (10 total doses).

Participants will need to track their doses and COVID-19 signs/symptoms in a diary.

This study may be an option for people who:

  • Are at least 18 years of age or older and weigh at least 40 kg (88 lbs.)
  • Have completed an initial 5-day course of PAXLOVID and experienced initial improvement in COVID-19 signs/symptoms followed by a worsening (rebound) of COVID-19 signs/ symptoms
  • Are willing to take a COVID-19 test at a study site within 48 hours of first rebound symptom


There are other requirements to participate in this study. A study team member will help determine if this study is right for you.

Close
Check your eligibility

Eligibility Checker